金迪克：10月24日召开董事会会议

Group 1 - The company, Jindike, announced that its second board meeting will be held on October 24, 2025, to discuss the cancellation of the supervisory board and amendments to the company’s articles of association [1] - For the year 2024, Jindike's revenue composition is entirely from biopharmaceuticals, accounting for 100.0% [1] - As of the report date, Jindike's market capitalization is 2.1 billion yuan [2] Group 2 - The Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year [2] - The secondary market for biomedicine is experiencing a boom, while the primary market is facing challenges in fundraising [2]